Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University.